ALLIANCE PHARMA PLC

Legal Proceedings Report • May 23, 2019

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 9607Z

Alliance Pharma PLC

23 May 2019

	23 May 2019

ALLIANCE PHARMA PLC

("Alliance" or the "Company")

Comment on CMA Statement of Objections

Alliance Pharma plc (AIM: APH), the international healthcare group, notes the announcement this morning from the Competition and Markets Authority ("CMA") that it has issued a Statement of Objections to a number of companies including Alliance alleging anti-competitive agreements in relation to the sale of prescription prochlorperazine, one of the smaller products in Alliance's portfolio which had peak sales in 2015 of £1.9m and sales of less than £0.2m in 2018.

Alliance confirms that it has had no involvement in the pricing or distribution of prochlorperazine since 2013, when it was out-licensed by the Company to Focus Pharmaceuticals Limited on an exclusive basis as is normal market practice. Alliance has not had control of or influence on, and nor has it benefited from, any price increases.

Prior to 2013, prochlorperazine was marketed directly by the Company.

Alliance will review the Statement of Objections in detail and work closely with the CMA to resolve its alleged objections. Alliance strongly condemns anti-competitive practices.

Further announcements will be made as appropriate.

For further information:

Alliance Pharma plc	+ 44 (0)1249 466966
Peter Butterfield, Chief Executive Officer
Andrew Franklin, Chief Financial Officer Chris Chrysanthou, Head of Legal and Company Secretary
www.alliancepharma.co.uk
Buchanan	+ 44 (0)20 7466 5000
Mark Court / Sophie Wills / Hannah Ratcliff
Numis Securities Limited	+ 44 (0)20 7260 1000
Nominated Adviser: Freddie Barnfield / Freddie Naylor-Leyland
Corporate Broking: James Black
Investec Bank plc Corporate Finance: Daniel Adams / Ed Thomas Corporate Broking: Patrick Robb / Tejas Padalkar	+ 44 (0)20 7597 5970

About Alliance

Alliance Pharma plc (AIM: APH) is an international healthcare group, headquartered in the UK with affiliate offices in Europe, the Far East and the US and wide international reach through an extensive network of distributors, generating sales in more than 100 countries.

We currently own or license the rights to more than 90 pharmaceutical and consumer healthcare products, which are managed on a portfolio basis according to their growth potential. Promotional investment is focussed on a small number of brands with significant international or multi-territory reach. The remainder of the portfolio comprises products which are sold in a limited number of local markets and require little or no promotional investment.

Our tried and tested 'Buy and Build' strategy, allows us to benefit both from organic growth opportunities and from enhancing our growth rate through carefully selected acquisitions.

For more information on Alliance, please visit our website:  www.alliancepharmaceuticals.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

MSCDMGZKKFFGLZG